American Heart Association Scientific Sessions 2025

Business news, market intelligence, and global industry analysis.

Amgen’s landmark Repatha trial to take center stage at AHA 2025 with major cardiovascular prevention results

Find out how Amgen’s Repatha phase 3 trial is redefining cardiovascular prevention and reshaping investor sentiment at AHA 2025.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

October 31, 2025